Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

Intermediate-risk acute myeloid leukemia (IR-AML) is a clinically heterogeneous disease, for which optimal post-remission therapy is debated. The utility of next-generation sequencing information in decision making for IR-AML has yet to be elucidated. We retrospectively studied 100 IR-AML patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Saygin, Caner, Hirsch, Cassandra, Przychodzen, Bartlomiej, Sekeres, Mikkael A., Hamilton, Betty K., Kalaycio, Matt, Carraway, Hetty E., Gerds, Aaron T., Mukherjee, Sudipto, Nazha, Aziz, Sobecks, Ronald, Goebel, Christopher, Abounader, Donna, Maciejewski, Jaroslaw P., Advani, Anjali S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802549/
https://www.ncbi.nlm.nih.gov/pubmed/29321554
http://dx.doi.org/10.1038/s41408-017-0040-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802549/
https://www.ncbi.nlm.nih.gov/pubmed/29321554
http://dx.doi.org/10.1038/s41408-017-0040-9

Ejemplares similares